Document:

ecyt_Ex10_16

		
			Exhibit 10.16
		

		
			CONFIDENTIAL TREATMENT REQUESTED
		

		
			Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for confidential treatment.
		

		
			 
		

			
					
						 

				
	
					
						AMENDMENT #3

					
						TO LICENSE AGREEMENT ID LA3190Endocyte

					
						Between Purdue Research Foundation and Endocyte, Inc.

				

		
			 
		

		
			THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Exclusive License Agreement (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with an effective date of March 1, 2010.
		

		
			NOW THEREFORE, the parties hereto do hereby agree as follows:
		

			
	
			
				 1.
			

			
	
			
			The following Eligible Disclosure is added to Appendix A of the AGREEMENT:

			
					
						Title of Eligible Disclosure:

					
					
						[*]

				
	
					
						PRF Ref. No.

					
					
						67710

				
	
					
						Contributors of the Eligible Disclosure:

					
					
						Phil Low-Purdue University

					
						Andrea Kasinski-Purdue University

					
						Loganathan Rangasamy-Purdue University

				

		
			 
		

			
	
			
				 2.
			

			
	
			
			The following Patents are added to Appendix A of the Agreement:

			
					
						PRF Ref #

					
					
						Title of Application

					
					
						Application Number

					
					
						Inventors

					
					
						Filing Date

					
					
						Country

					
					
						Status

				
	
					
						67710-01

					
					
						[*]

					
					
						[*]

					
					
						Phil Low-Purdue University

					
						Andrea Kasinski-Purdue University

					
						Loganathan Rangasamy-Purdue University 

					
					
						11/16/16

					
					
						US

					
					
						Filed

				

			
	
			
				 3.
			

			
	
			
			 The rights granted to the above Eligible Disclosure and Patents are limited to use where the primary target of the Ligand is directed to the prostate membrane antigen receptor. 

			
	
			
				 4.
			

			
	
			
			All other terms and conditions of the AGREEMENT remain unchanged and in effect.

		
			IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.
		

		
			

		 

		

			 [*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

		

		

			 

		

		

			 

		

 

		

		
			Purdue Research FoundationEndocyte, Inc.
		

		
			By: _/s/ Brooke Beier__________By: _/s/ Mike Sherman________________
		

		
			Name: Brooke Beier                           Name: Mike Sherman
		

		
			 
		

		
			Title:   Executive Director, OTC  Title:  President & CEO
		

		 

		

			[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.ecyt_Ex10_19

		
			 
		

		
			Exhibit 10.19
		

		
			CONFIDENTIAL TREATMENT REQUESTED
		

		
			Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for confidential treatment.
		

			
					
						 

				
	
					
						AMENDMENT #9

					
						TO LIENSE AGREEMENT ID 2014-0052

					
						Between Purdue Research Foundation and Endocyte, Inc.

				

		
			 
		

		
			THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”) between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte, Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in this Agreement.
		

		
			WHEREAS, Purdue University continues to develop technologies and scientific advances in the laboratory of Professor Philip Low funded by Endocyte, Inc.; and 
		

		
			WHEREAS, Endocyte wishes to continue licensing such technologies and scientific advances under the Agreement,
		

		
			NOW THEREFORE, the parties hereto do hereby agree as follows:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			The following Elected Eligible Disclosure is added to Schedule A for a Target under Section 1.20(ii):

		
			 
		

			
					
						Title of Elected Eligible Disclosure

					
					
						[*]

				
	
					
						PRF Reference Number of Elected Eligible Disclosure

					
					
						67750

				
	
					
						Contributors of the Elected Eligible Disclosure

					
					
						Philip S. Low and Jyoti Roy

				

		
			 
		

			
	
			
				 2.
			

			
	
			
			The following Licensed Patents are added to Schedule A of the Agreement for a Target under Section 1.20(ii). 

		
			 
		

		

		 

		

			[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

		

		

			 

		

		

			 

		

 

	
					
						

					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						PRF Ref #

					
					
						Title of Application

					
					
						Application Number

					
					
						Inventors

					
					
						Filing Date

					
					
						Country

					
					
						Status

				
	
					
						67750-01

					
					
						[*]

					
					
						[*]

					
					
						Philip S. Low and Jyoti Roy

					
					
						12/14/2016

					
					
						US (Provisional)

					
					
						Filed

				
	
					
						67750-02

					
					
						[*]

					
					
						[*]

					
					
						Philip S. Low and Jyoti Roy

					
					
						3/6/2017

					
					
						US (Provisional)

					
					
						Filed

				

		
			 
		

		
			All other terms and conditions of the original agreement remain unchanged and in effect.
		

		
			IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
		

		
			 
		

		
			Purdue Research FoundationEndocyte, Inc.
		

		
			By: _/s/ Brooke Beier____________By: _/s/ Mike Sherman__________
		

		
			Name:Brooke Beier              Name:  Mike Sherman
		

		
			 
		

		
			Title: Executive Director, OTC           Title:  President & CEO
		

		
			 
		

		
			Date:     11-08-2017                        Date:     11-01-17    
		

		
			
		

		

		 

		

			[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

		

		

			 

		

		

			 

		

 

	
					
						

					
						 

				
	
					
						AMENDMENT #10

					
						TO LICENSE AGREEMENT ID 2014-0052

					
						Between Purdue Research Foundation and Endocyte, Inc.

				

		
			 
		

		
			THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”) between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte, Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in this Agreement.
		

		
			WHEREAS, Purdue University continues to develop technologies and scientific advances in the laboratory of Professor Philip Low funded by Endocyte, Inc.; and 
		

		
			WHEREAS, Endocyte wishes to continue licensing such technologies and scientific advances under the Agreement,
		

		
			NOW THEREFORE, the parties hereto do hereby agree as follows:
		

			
	
			
				 1.
			

			
	
			
			The following Elected Eligible Disclosure is added to Schedule A of the Agreement for a Target under Section 1.20(ii).

		
			 
		

			
					
						Title of Elected Eligible Disclosure

					
					
						
[*]

				
	
					
						PRF Reference Number of Elected Eligible Disclosure

					
					
						67751

				
	
					
						Contributors of the Elected Eligible Disclosure

					
					
						Philip S. Low and Jyoti Roy

				

		
			 
		

			
	
			
				 2.
			

			
	
			
			The following Licensed Patents are added to Schedule A of the Agreement for a Target under Section 1.20(ii). 

			
					
						PRF Ref #

					
					
						Title

					
					
						App #

					
					
						Inventors

					
					
						Filing Date

					
					
						Country

					
					
						Status

				
	
					
						67751-01

					
					
						[*]

					
					
						[*]

					
					
						Philip S. Low

					
						Jyoti Roy

					
					
						December 14, 2016

					
					
						US (provisional)

					
					
						Filed

				

		
			 
		

		
			All other terms and conditions of the original agreement remain unchanged and in effect.
		

		
			IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
		

		
			

		 

		

			[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

		

		

			 

		

		

			 

		

 

		

		
			 
		

		
			Purdue Research FoundationEndocyte, Inc.
		

		
			By: _/s/ Brooke Beier__________By: _/s/ Mike Sherman___________
		

		
			Name:Brooke Beier              Name:  Mike Sherman
		

		
			 
		

		
			Title: Executive Director, OTC           Title:  President & CEO
		

		
			 
		

		
			Date:      November 8, 2017    Date:    11-01-17   
		

		
			 
		

		 

		

			[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]